drugset / Trial / NCT05163314
A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome
NaSingle-groupOpen-labelTreatment
Summary
The main aim of the study is to learn if soticlestat, when given as an add-on therapy, reduces the number of seizures in children and adults with Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS). Participants will receive their standard anti-seizure therapy, plus tablets of soticlestat. There will be scheduled visits and follow-up phone calls throughout the study.
Timeline
- Start
- 2022-03-04
- Primary completion
- 2025-09-24
- Completion
- 2025-09-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Soticlestat | Small molecule | 100 mg | Oral |
| Subject | Soticlestat | Small molecule | 200 mg | Oral |
| Subject | Soticlestat | Small molecule | 300 mg | Oral |